• Eveliqure Announces NIAID Contract to Study Shigella, ETEC Vaccine Candidate americanpharmaceuticalreview
    September 14, 2020
    Eveliqure Biotechnologies GmbH announced the award of a US government contract from the National Institute of Allergy and Infectious Diseases (NIAID), contract #75N93020C00048 with the intent to fund the development of its vaccine candidate, ShigETEC ...
PharmaSources Customer Service